BR112017015287A2 - anticorpos para fcrn e métodos de uso dos mesmos - Google Patents

anticorpos para fcrn e métodos de uso dos mesmos

Info

Publication number
BR112017015287A2
BR112017015287A2 BR112017015287-8A BR112017015287A BR112017015287A2 BR 112017015287 A2 BR112017015287 A2 BR 112017015287A2 BR 112017015287 A BR112017015287 A BR 112017015287A BR 112017015287 A2 BR112017015287 A2 BR 112017015287A2
Authority
BR
Brazil
Prior art keywords
subject
antibodies
blocking
fcrn
methods
Prior art date
Application number
BR112017015287-8A
Other languages
English (en)
Inventor
Kehry Marilyn
J. King David
E. Ling Leona
Meador James Iii
Roy Sucharita
Manning Anthony
Original Assignee
Momenta Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceutical, Inc. filed Critical Momenta Pharmaceutical, Inc.
Publication of BR112017015287A2 publication Critical patent/BR112017015287A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção apresenta anticorpos que têm elevada afinidade de ligação quanto ao receptor fc (fcrn) neonatal humano. estes anticorpos antifcrn são úteis, por exemplo, para promover a eliminação de autoanticorpos em um sujeito, para suprimir a apresentação de antígenos em um sujeito, para bloquear uma resposta imune, por exemplo, bloquear uma ativação baseada em complexos imunes da resposta imune em um sujeito e para tratar doenças imunológicas (por exemplo, doenças autoimunes) em um sujeito.
BR112017015287-8A 2015-01-30 2016-01-29 anticorpos para fcrn e métodos de uso dos mesmos BR112017015287A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562110071P 2015-01-30 2015-01-30
US62/110,071 2015-01-30
US201562258082P 2015-11-20 2015-11-20
US62/258,082 2015-11-20
PCT/US2016/015720 WO2016123521A2 (en) 2015-01-30 2016-01-29 Fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112017015287A2 true BR112017015287A2 (pt) 2018-01-16

Family

ID=56544538

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015287-8A BR112017015287A2 (pt) 2015-01-30 2016-01-29 anticorpos para fcrn e métodos de uso dos mesmos

Country Status (21)

Country Link
US (2) US10676526B2 (pt)
EP (2) EP3250610B1 (pt)
JP (2) JP6853178B2 (pt)
KR (2) KR20230007545A (pt)
CN (2) CN113384693A (pt)
AU (2) AU2016211280B2 (pt)
BR (1) BR112017015287A2 (pt)
CA (1) CA2972822A1 (pt)
DK (1) DK3250610T3 (pt)
ES (1) ES2962824T3 (pt)
FI (1) FI3250610T3 (pt)
HR (1) HRP20231399T1 (pt)
HU (1) HUE063778T2 (pt)
IL (1) IL252837B (pt)
LT (1) LT3250610T (pt)
PL (1) PL3250610T3 (pt)
PT (1) PT3250610T (pt)
RS (1) RS64768B1 (pt)
SG (2) SG11201705475QA (pt)
SI (1) SI3250610T1 (pt)
WO (1) WO2016123521A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142843A (zh) 2013-12-24 2020-12-29 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
EP3155013B1 (en) * 2014-06-12 2019-03-27 F. Hoffmann-La Roche AG Method for selecting antibodies with modified fcrn interaction
WO2016123521A2 (en) 2015-01-30 2016-08-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
DK3491025T3 (da) * 2016-07-29 2024-01-15 Momenta Pharmaceuticals Inc Fcrn-antistoffer og anvendelsesmetoder heraf
WO2018229249A1 (en) * 2017-06-15 2018-12-20 Ucb Biopharma Sprl Method for the treatment of immune thrombocytopenia
WO2019118791A1 (en) * 2017-12-13 2019-06-20 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
US20200024344A1 (en) 2018-06-08 2020-01-23 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
EA202190264A1 (ru) * 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
EA202190335A1 (ru) * 2018-07-20 2021-06-11 Момента Фармасьютикалз, Инк. Композиции антител против fcrn и способы их применения
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
MX2021014756A (es) 2019-06-07 2022-01-18 Argenx Bvba Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea.
WO2021022249A1 (en) * 2019-08-01 2021-02-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
US20230049011A1 (en) * 2019-11-19 2023-02-16 Immunovant Sciences Gmbh Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
EP4240417A1 (en) * 2020-11-06 2023-09-13 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2022166900A1 (en) * 2021-02-02 2022-08-11 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
CN116234827A (zh) * 2021-09-03 2023-06-06 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536709T3 (es) 2002-02-14 2015-05-27 Chugai Seiyaku Kabushiki Kaisha Utilización de ácido acético para eliminar los problemas inducidos por el ión Fe en las formulaciones de anticuerpos anti-HM1.24 o anti-IL6R
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
EP1660128A4 (en) * 2003-08-08 2009-01-21 Univ New York State Res Found ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
BRPI0608855A2 (pt) 2005-03-08 2010-02-02 Pharmacia & Upjohn Co Llc composições de anticorpo anti - madcam processo para a preparação das mesmas e uso de anticorpo anti - madcam
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
CN101421297A (zh) * 2006-02-17 2009-04-29 森托尼克斯制药有限公司 阻断lgG对FcRn的结合的肽
CA2644405A1 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
KR101634719B1 (ko) * 2008-04-25 2016-06-29 다이액스 코포레이션 Ｆｃｒｎ에 대한 항체 및 이들의 용도
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
CN103619353B (zh) 2011-06-02 2016-01-06 戴埃克斯有限公司 Fc受体结合蛋白
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
WO2014099636A1 (en) 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
EP3719122A1 (en) 2013-05-02 2020-10-07 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
WO2016123521A2 (en) * 2015-01-30 2016-08-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
MY188761A (en) * 2015-03-09 2021-12-29 Argenx Bvba Method of reducing serum levels of fc-containing agents using fcrn antagonists
WO2016183352A1 (en) 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
DK3491025T3 (da) 2016-07-29 2024-01-15 Momenta Pharmaceuticals Inc Fcrn-antistoffer og anvendelsesmetoder heraf
EP3720877A1 (en) 2017-12-08 2020-10-14 Argenx BVBA Use of fcrn antagonists for treatment of generalized myasthenia gravis
WO2019118791A1 (en) 2017-12-13 2019-06-20 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
EA202190335A1 (ru) 2018-07-20 2021-06-11 Момента Фармасьютикалз, Инк. Композиции антител против fcrn и способы их применения

Also Published As

Publication number Publication date
IL252837A0 (en) 2017-08-31
US11732047B2 (en) 2023-08-22
KR20170109020A (ko) 2017-09-27
SG10202007232WA (en) 2020-09-29
AU2016211280B2 (en) 2021-11-25
EP3250610B1 (en) 2023-08-09
SG11201705475QA (en) 2017-08-30
DK3250610T3 (da) 2023-10-30
KR102483016B1 (ko) 2023-01-03
EP3250610A4 (en) 2018-08-22
KR20230007545A (ko) 2023-01-12
LT3250610T (lt) 2023-09-25
CA2972822A1 (en) 2016-08-04
WO2016123521A3 (en) 2016-09-22
ES2962824T3 (es) 2024-03-21
EP4286011A2 (en) 2023-12-06
AU2022201145A1 (en) 2022-03-17
EP3250610A2 (en) 2017-12-06
HUE063778T2 (hu) 2024-01-28
US20180016334A1 (en) 2018-01-18
CN107567460A (zh) 2018-01-09
AU2016211280A1 (en) 2017-07-13
JP6853178B2 (ja) 2021-03-31
US10676526B2 (en) 2020-06-09
IL252837B (en) 2021-10-31
JP2021061854A (ja) 2021-04-22
JP2018504907A (ja) 2018-02-22
PL3250610T3 (pl) 2024-01-29
PT3250610T (pt) 2023-11-13
SI3250610T1 (sl) 2023-11-30
CN107567460B (zh) 2021-04-23
EP4286011A3 (en) 2024-02-14
HRP20231399T1 (hr) 2024-02-16
JP7224382B2 (ja) 2023-02-17
CN113384693A (zh) 2021-09-14
WO2016123521A2 (en) 2016-08-04
FI3250610T3 (fi) 2023-11-01
US20200299382A1 (en) 2020-09-24
RS64768B1 (sr) 2023-11-30

Similar Documents

Publication Publication Date Title
BR112017015287A2 (pt) anticorpos para fcrn e métodos de uso dos mesmos
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CU20160101A7 (es) Inmunoglobulina con fab en tándem
BR112018015485A2 (pt) imunoglobulina fabs-in-tandem e usos da mesma
BR112016016699A2 (pt) Anticorpos humanos para pd-1
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
BR112017018770A2 (pt) redução da tolerância imunológica induzida por pd-l1
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
MX2018011503A (es) Proteinas de union y metodos de uso de las mismas.
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
BR112019001806A2 (pt) anticorpos para fcrn e métodos de uso dos mesmos
PH12016500943A1 (en) Aplnr modulatros and uses thereof
GEP201706794B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
EA036814B9 (ru) Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
EA201790192A1 (ru) СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
UY36302A (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: MOMENTA PHARMACEUTICAL, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]